Cancer Research AACR Legacy Sign up for Cancer Research eTOC's
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
[Cancer Research 59, 3134-3142, July 1, 1999]
© 1999 American Association for Cancer Research
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Butterfield, L. H.
Right arrow Articles by Economou, J. S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Butterfield, L. H.
Right arrow Articles by Economou, J. S.
[Cancer Research 59, 3134-3142, July 1, 1999]
© 1999 American Association for Cancer Research

Immunology

Generation of Human T-cell Responses to an HLA-A2.1-restricted Peptide Epitope Derived from {alpha}-Fetoprotein1

Lisa H. Butterfield, Andrew Koh, Wilson Meng, Charles M. Vollmer, Antoni Ribas, Vivian Dissette, Eric Lee, John A. Glaspy, William H. McBride and James S. Economou2

Divisions of Surgical Oncology [L. H. B., A. K., W. M., C. M. V., A. R., V. D., E. L., J. S. E.], Hematology/Oncology [A. R., J. A. G.], and Experimental Radiation Oncology [W. H. M.], University of California Los Angeles Medical Center, University of California Los Angeles, Los Angeles, California 90095

{alpha}-Fetoprotein (AFP) is often derepressed in human hepatocellular carcinoma. Peptide fragments of AFP presented in the context of major histocompatibility molecules could serve as potential recognition targets by CD8 T cells, provided these lymphocytes were not clonally deleted in ontogeny. We therefore wished to determine whether the human T-cell repertoire could recognize AFP-derived peptide epitopes in the context of a common class I allele, HLA-A2.1. Dendritic cells genetically engineered to express AFP were capable of generating AFP-specific T-cell responses in autologous human lymphocyte cultures and in HLA-A2.1/Kb transgenic mice. These T cells recognize a 9-mer peptide derived from the AFP protein hAFP542–550 (GVALQTMKQ). Identified as a potential A2.1-restricted peptide epitope from a computer analysis of the AFP sequence, hAFP542–550 proved to have low binding affinity to A2.1, but slow off-kinetics. AFP-specific CTL- and IFN-{gamma}-producing cells recognize hAFP542–550-pulsed targets. Conversely, hAFP542–550 peptide-generated T cells from both human lymphocyte cultures and A2.1/Kb transgenic mice recognized AFP-transfected targets in both cytotoxicity assays and cytokine release assays. These lines of evidence clearly demonstrate that AFP-reactive clones have not been deleted from the human T-cell repertoire and identify one immunodominant A2.1-restricted epitope. These findings also clearly establish AFP as a potential target for T-cell-based immunotherapy.




This article has been cited by other articles:


Home page
 Clin. Cancer Res.Home page
H. Ishizaki, T. Tsunoda, S. Wada, M. Yamauchi, M. Shibuya, and H. Tahara
Inhibition of tumor growth with antiangiogenic cancer vaccine using epitope peptides derived from human vascular endothelial growth factor receptor 1.
Clin. Cancer Res., October 1, 2006; 12(19): 5841 - 5849.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
Y. Liu, S. Daley, V. N. Evdokimova, D. D. Zdobinski, D. M. Potter, and L. H. Butterfield
Hierarchy of {alpha} Fetoprotein (AFP)-Specific T Cell Responses in Subjects with AFP-Positive Hepatocellular Cancer
J. Immunol., July 1, 2006; 177(1): 712 - 721.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
L. H. Butterfield, A. Ribas, V. B. Dissette, Y. Lee, J. Q. Yang, P. De la Rocha, S. D. Duran, J. Hernandez, E. Seja, D. M. Potter, et al.
A Phase I/II Trial Testing Immunization of Hepatocellular Carcinoma Patients with Dendritic Cells Pulsed with Four {alpha}-Fetoprotein Peptides.
Clin. Cancer Res., May 1, 2006; 12(9): 2817 - 2825.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
A. Alisa, A. Ives, A. A. Pathan, C. V. Navarrete, R. Williams, A. Bertoletti, and S. Behboudi
Analysis of CD4+ T-Cell Responses to a Novel {alpha}-Fetoprotein-Derived Epitope in Hepatocellular Carcinoma Patients
Clin. Cancer Res., September 15, 2005; 11(18): 6686 - 6694.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
S. Wada, T. Tsunoda, T. Baba, F. J. Primus, H. Kuwano, M. Shibuya, and H. Tahara
Rationale for Antiangiogenic Cancer Therapy with Vaccination Using Epitope Peptides Derived from Human Vascular Endothelial Growth Factor Receptor 2
Cancer Res., June 1, 2005; 65(11): 4939 - 4946.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
N. Uchida, T. Tsunoda, S. Wada, Y. Furukawa, Y. Nakamura, and H. Tahara
Ring Finger Protein 43 as a New Target for Cancer Immunotherapy
Clin. Cancer Res., December 15, 2004; 10(24): 8577 - 8586.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
Y.-P. Liao, C.-C. Wang, L. H. Butterfield, J. S. Economou, A. Ribas, W. S. Meng, K. S. Iwamoto, and W. H. McBride
Ionizing Radiation Affects Human MART-1 Melanoma Antigen Processing and Presentation by Dendritic Cells
J. Immunol., August 15, 2004; 173(4): 2462 - 2469.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
F. Korangy, L. A. Ormandy, J. S. Bleck, J. Klempnauer, L. Wilkens, M. P. Manns, and T. F. Greten
Spontaneous Tumor-Specific Humoral and Cellular Immune Responses to NY-ESO-1 in Hepatocellular Carcinoma
Clin. Cancer Res., July 1, 2004; 10(13): 4332 - 4341.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
A. Ribas, J. A. Wargo, B. Comin-Anduix, S. Sanetti, L. Y. Schumacher, C. McLean, V. B. Dissette, J. A. Glaspy, W. H. McBride, L. H. Butterfield, et al.
Enhanced Tumor Responses to Dendritic Cells in the Absence of CD8-Positive Cells
J. Immunol., April 15, 2004; 172(8): 4762 - 4769.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
L. H. Butterfield, A. Ribas, W. S. Meng, V. B. Dissette, S. Amarnani, H. T. Vu, E. Seja, K. Todd, J. A. Glaspy, W. H. McBride, et al.
T-Cell Responses to HLA-A*0201 Immunodominant Peptides Derived from {alpha}-Fetoprotein in Patients with Hepatocellular Cancer
Clin. Cancer Res., December 1, 2003; 9(16): 5902 - 5908.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
M. R. Parkhurst, C. DePan, J. P. Riley, S. A. Rosenberg, and S. Shu
Hybrids of Dendritic Cells and Tumor Cells Generated by Electrofusion Simultaneously Present Immunodominant Epitopes from Multiple Human Tumor-Associated Antigens in the Context of MHC Class I and Class II Molecules
J. Immunol., May 15, 2003; 170(10): 5317 - 5325.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
L. H. Butterfield, A. Ribas, V. B. Dissette, S. N. Amarnani, H. T. Vu, D. Oseguera, H.-J. Wang, R. M. Elashoff, W. H. McBride, B. Mukherji, et al.
Determinant Spreading Associated with Clinical Response in Dendritic Cell-based Immunotherapy for Malignant Melanoma
Clin. Cancer Res., March 1, 2003; 9(3): 998 - 1008.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
A. M. Krackhardt, M. Witzens, S. Harig, F. S. Hodi, A. J. Zauls, M. Chessia, P. Barrett, and J. G. Gribben
Identification of tumor-associated antigens in chronic lymphocytic leukemia by SEREX
Blood, August 28, 2002; 100(6): 2123 - 2131.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
W. S. Meng, L. H. Butterfield, A. Ribas, V. B. Dissette, J. B. Heller, G. A. Miranda, J. A. Glaspy, W. H. McBride, and J. S. Economou
{alpha}-Fetoprotein-specific Tumor Immunity Induced by Plasmid Prime-Adenovirus Boost Genetic Vaccination
Cancer Res., December 1, 2001; 61(24): 8782 - 8786.
[Abstract] [Full Text] [PDF]

Home page
 Exp. Biol. Med.Home page
G. J. Mizejewski
Alpha-fetoprotein Structure and Function: Relevance to Isoforms, Epitopes, and Conformational Variants
Experimental Biology and Medicine, May 1, 2001; 226(5): 377 - 408.
[Abstract] [Full Text]

Home page
 J. Immunol.Home page
L. H. Butterfield, W. S. Meng, A. Koh, C. M. Vollmer, A. Ribas, V. B. Dissette, K. Faull, J. A. Glaspy, W. H. McBride, and J. S. Economou
T Cell Responses to HLA-A*0201-Restricted Peptides Derived from Human {{alpha}} Fetoprotein
J. Immunol., April 15, 2001; 166(8): 5300 - 5308.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
T. Nishiyama, M. Tachibana, Y. Horiguchi, K. Nakamura, Y. Ikeda, K. Takesako, and M. Murai
Immunotherapy of Bladder Cancer Using Autologous Dendritic Cells Pulsed with Human Lymphocyte Antigen-A24-specific MAGE-3 Peptide
Clin. Cancer Res., January 1, 2001; 7(1): 23 - 31.
[Abstract] [Full Text]

Home page
 J. Immunol.Home page
R. P. M. Sutmuller, L. R. H. M. Schurmans, L. M. van Duivenvoorde, J. A. Tine, E. I. H. van der Voort, R. E. M. Toes, C. J. M. Melief, M. J. Jager, and R. Offringa
Adoptive T Cell Immunotherapy of Human Uveal Melanoma Targeting gp100
J. Immunol., December 15, 2000; 165(12): 7308 - 7315.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
A. Ribas, L. H. Butterfield, and J. S. Economou
Genetic Immunotherapy for Cancer
Oncologist, April 1, 2000; 5(2): 87 - 98.
[Abstract] [Full Text]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 1999 by the American Association for Cancer Research.